Peter Bou Dib: New Insights on Factor VIII and the Musculoskeletal System
Peter Bou Dib, Key Account Manager at Sino Biological Europe, shared on LinkedIn about a recent article by Antoine Babuty et al, published in Nature Bone Research:
”Hemophilia A (HA) has long been known as a bleeding disorder caused by deficient Factor VIII (FVIII), leading to life-impacting joint bleeds and muscle degeneration.
But what if FVIII’s role extends far beyond just stopping bleeds?
A recently published study using FVIII knockout mice uncovered a surprising story: FVIII deficiency triggers early osteoporosis, disrupted bone vascularization, and muscle abnormalities
a complex musculoskeletal disruption that mirrors patients’ real-life challenges.
Even more promising, intravenous recombinant FVIII treatment not only restored bone density and vascular health but partially reversed muscle metabolic defects.
This suggests FVIII acts as a critical regulator of bone remodeling and muscle metabolism, not just coagulation.
For those living with HA, these insights kindle hope for therapies that protect bones and muscles, improving quality of life beyond bleeding control.
Science is rewriting what we know about FVIII, transforming how we understand, treat, and support hemophilia.
The journey continues.”
Title: Factor VIII restores bone parameters and modulates muscle proteo-metabolome in Factor VIII knockout male mice
Authors: Antoine Babuty, Javier Muñoz-Garcia, Olivier D. Christophe, Laurie Fradet, Manon Taupin, Denis Cochonneau, Emilie Ollivier, Frank Driessler, Claudia Lange, Oleksandr Boychenko, Marie-Françoise Heymann, Dominique Heymann
Read the Full Article on Nature Bone Research
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 5, 2026, 19:20Yubrine Moraa Gachemba: BETULA Adds New Evidence for Catheter-Directed Thrombolysis in PE
-
Sep 5, 2026, 19:18John R. Mehall: The Importance of Anticoagulation Management in ECMO
-
Sep 5, 2026, 19:16Thirunavukkarasu Angappan: Why Hemophilia B Still Needs Both Plasma-Derived and Recombinant Factor IX
-
Sep 5, 2026, 19:15Michelle Leona Cecil: Comprehensive Hemophilia Care Doesn’t Begin and End With One Appointment
-
Sep 5, 2026, 19:13Amparo Santamaria: Stem Cells and Hematology – Unlocking a New Frontier in Ovarian Regeneration
-
Sep 5, 2026, 19:10Strengthening the Public Health System for Blood Disorders – Hemophilia Federation of America
-
Sep 5, 2026, 19:08Deidra D. Harris: Supporting Hemophilia of Georgia and the Bleeding Disorders Community
-
Sep 5, 2026, 19:06Katherine Blackwell: Blessed to Have the Opportunity to Speak at the Hemophilia of Indiana Annual Meeting
-
Sep 5, 2026, 19:04Christy V.: What You Need to Know about GI Bleeding and Hemophilia